RISCAID: Remote Ischemic Conditioning for Angiopathy in Diabetes

Remote ischemic conditioning (RIC) is at non-invasive non-pharmacological treatment which has been shown to attenuate tissue damage caused by ischemia e.g. in hearts subjected to ischemia. RIC treatment consists of brief repetitive periods of ischemia induced in an extremity e.g. an arm. Recent findings show that six week RIC treatment improves healing of diabetic foot ulcers, suggesting a possible effect on the underlying pathological causes of ulcers e.g. PAD.    


The overall aim of this study is to investigate if long-term ambulatory remote ischemic conditioning can improve symptoms and signs of peripheral arterial disease and neuropathy in patients with type 2 diabetes. 

Design and method

 A single center double-blinded randomized placebo controlled study investigating the efficacy of home based 12-week RIC treatment on markers of vascular, neuronal function, inflammation and serum lipid composition in 40 type 2 diabetes patients from Steno Diabetes Center with non-critical PAD.  

Target group

Type 2 diabetes patients age 40-80 with moderate peripheral arterial disease (toe pressure from 40 mmHG to 70 mmHg)

Expected ending and outcome

The study will generate data for 3-4 publications and serve as a base for evaluation of the feasibility of a full scale study with walking distance as primary outcome. 
Study end: spring 2017


Peter Rossing, professor, MD, head of the complication group at SDCC
Marit Eika Jørgensen, professor, MD, head of Clinical Epidemiology at SDCC. Christian Stevns Hansen, MD, PhD.
Hans Erik Bøtker, MD, Cardiologist, professor at Skeiby University Hospital.
Christian Herder, assistant professor, PhD, MSc, German Diabetes Center, Dusseldorf, Germany.
Dan Ziegler, MD, professor, institute for Clinical Diabetology.
Michael Roden professor, dr. head of institute for Clinical Diabetology.

Responsible editor